Biotechnology
featured
*KDDI lifts full-year earnings forecast. *HSBC cuts Japan rating, BNP sees index rising to 13,000.
» Read MoreMore
-
*KDDI lifts full-year earnings forecast. *HSBC cuts Japan rating, BNP sees index rising to 13,000.
-
An internal analysis conducted by Johnson & Johnson in 2011 estimated that the all-metal device would fail within five years in nearly 40 percent of patients who received it, newly disclosed court records show.
-
Biotech stocks are outperforming the major indices, and are up 3 percent over the past week. CNBC's Seema Mody is tracking which stocks are trending on Twitter.
-
Eli Lilly will be "very challenged" by the loss of exclusivity on several blockbuster drugs, CEO John Lechleiter told CNBC on Tuesday, but added the company can manage its growth in response.
-
Charles River Laboratories CEO James Foster discusses competition in the drug market, drug patents and where his business is headed in 2013.
-
Rock bottom interest rates will likely boost key stocks in the biotechnology sector, but Obamacare will dampen prospects for HMO shares.
-
"As a group, biotech is the place to be this year," said," Les Funtleyder, Poliwogg fund manager, discussing where to find attractive health care opportunities in 2013.
-
The iShare Biotech ETF is up 32 percent over the past year. Jean-Jacques Bienaime, BioMarin Pharmaceutical CEO, discusses the reason behind his company behind up 24.9 percent in the last 3 months.
-
CNBC's Seema Mody reports the pharmaceutical and biotech sectors rally as the JPMorgan conference kicks off its second day.
-
Richard Pops, chairman & CEO at Alkermes, talks with CNBC's David Faber about positive developments in two key treatments in the company's pipeline.
-
The U.S. has given national security clearance to the purchase of an American DNA sequencing company by a Chinese firm, The New York Times reports.
-
Anti-virus software pioneer John McAfee is now firing back, reports CNBC's Robert Frank.
-
BRUSSELS, Nov 13- European lawmakers are challenging Malta's nominee for the EU's top health job because of his contempt for homosexuals and opposition to abortion, after his predecessor quit over an investigation linking him to bribery.
-
DuPont reported quarterly earnings and revenue that fell short of analysts' expectations on Tuesday, and announced plans to cut 1,500 jobs.
-
Pharmaceuticals continue to be an attractive sector for earnings and dividend growth, and CNBC's Seema Mody reports on how companies like Pfizer are faring.
-
If you're looking for beta, biotech might be your answer, reports CNBC's Seema Mody.
-
Thanks to several rounds of cost cutting and new product launches, cash balances across the pharma sector are increasing — because one analyst said we should see more cash being returned to shareholders via dividend.
-
Savient Pharmaceuticals has been taken to the woodshed, but recently it’s turned bullish.
-
The NYSE Arca Biotech index spacer hit an all-time high Monday, as investors continue to seek out the group for its above average growth prospects.
-
The Carlyle Group said it is buying DuPont's performance coatings business for $4.9 billion in cash, giving it another investment in the automotive and industrial segments.